BioStock: Cereno Scientific brings CVD expertise to CVCT Forum

As Cereno Scientific prepares to initiate its phase II trial with candidate CS1 in rare cardiovascular disease Pulmonary Arterial Hypertension, the company is taking the opportunity to participate in the CVCT Forum – an event that brings together Key Opinion Leaders within the field. BioStock reached out Cereno’s CMO Dr Björn Dahlöf as well as the forum’s chair and cofounder, Dr Faiez Zannad, to hear more about the overall importance of the Forum, how Cereno is contributing at the event, and what Cereno will gain from participating.

Read the Q&A with Björn Dahlöf and Faiez Zannad at biostock.se:

https://www.biostock.se/en/2021/12/cereno-scientific-brings-cvd-expertise-to-cvct-forum/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se